A feasibility study of combination therapy with trastuzumab, cyclophosphamide, and an allogeneic GM-CSF [granulocyte-macrophage colony-stimulating factor]-secreting breast tumor vaccine for the treatment of HER-2/Neu-overexpressing metastatic breast cancer.

Trial Profile

A feasibility study of combination therapy with trastuzumab, cyclophosphamide, and an allogeneic GM-CSF [granulocyte-macrophage colony-stimulating factor]-secreting breast tumor vaccine for the treatment of HER-2/Neu-overexpressing metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2012

At a glance

  • Drugs Breast cancer vaccine (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2012 Actual patient number is 22 according to ClinicalTrials.gov.
    • 25 Jan 2012 Actual patient number is 22 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top